Optimization of antibiotic dosing schedules in the light of increasing antibiotic resistance

References

• Gould IM. Pharmacodynamics and the relationship between in vitro and in vivo activity of antimicrobial agents. J. Chemother. 9\(Supp1.1), 74–83 (1997).
   Google Scholar
• Zhao X. Clarification of MPC and the mutant selection window concept. J. Antimicrob. Chemother. 52,731 (2003).
   PubMedGoogle Scholar
• Firsov AA, Vostrov SN, Lubenko TY, Drlica K, Portnoy YA, Zinner SH. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob. Agents. Chemother. 47(5), 1604–1613 (2003).
   Google Scholar
• ••Clearly shows, using an in vitro model,that resistant mutants are selected for when quinolone concentrations fall within the mutant selection window and that this may be used in clinical practice to predict dosing regimens that may prevent the development of resistance.
   Google Scholar
• Zinner SH, Lubenko TY, Gilbert D, et al. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that stimulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J. Antimicrob. Chemother. 52,616–622 (2003).
   PubMed Web of Science ®Google Scholar
• Freeman CD, Nicolau DP, Belliveau BP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J. Antimicrob. Chemother. 39,677–686 (1997).
   PubMed Web of Science ®Google Scholar
• Craig WA. Does the dose matter? Clin. Infect. Dis. 33\(Suppl. 3), S233—S237 (2001).
   Google Scholar
• Karlowsky JA, Zhanel GG, Davidson RJ, Hoban DJ. Once-daily aminoglycoside dosing assessed by MIC reversion time with Pseudomonas aeruginosa. Antimicrob. Agents. Chemother. 38(5), 1165–1168 (1994).
   Google Scholar
• Negri MC, Morosini MI, Loza E, Baquero F. In vitro selective antibiotic concentrations of B-lactams for penicillin-resistant Streptococcus pneumoniae populations. Antimicrob. Agents. Chemother. 38, 122–125 (1994).
   PubMedGoogle Scholar
• Odenhalt I, Gustafsson I, Lowdin E, Cars O. Suboptimal antibiotic dosage as a risk factor for selection of penicillin-resistant Streptococcus pneumoniae: in vitro kinetic model. Antimicrob. Agents. Chemother. 47(2), 518–523 (2003).
   PubMedGoogle Scholar
• Guillemot D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of B-Lactam. Risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 279(5), 365–370 (1998).
   Google Scholar
• •This prospective, randomized trial shows that short-course, high-dose amoxicillin therapy for the out-patient treatment of respiratory tract infections has the potential to reduce the spread of drug-resistant pneumo co cci.
   Google Scholar
• Schrag SJ, Pena C, Fernandez J, et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage. JAMA 286(1), 49–56 (2001).
   PubMedGoogle Scholar
• Dagan R, Klugman KP, Craig WA, Baquero F. Evidence to support the rational that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J. Antimicrob. Chemother. 47,129–140 (2001).
   PubMed Web of Science ®Google Scholar
• Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatric. Infect. Dis. J. 15,255–259 (1996).
   PubMed Web of Science ®Google Scholar
• Dabernat H, Geslin P, Megraud F, et al. Effects of cefixime or co-amoxidav treatment on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media. J. Antimicrob. Chemother. 41, 253–258 (1998).
   PubMedGoogle Scholar
• Pankuch GA, Jueneman SA, Davies TA, Jacobs MR, Applebaum PC. In vitro selection of reistance to four 11-lactams and azithromycin in Streptococcus pneumoniae. Antimicrob. Agents. Chemother. 42, 2914–2918 (1998).
   PubMed Web of Science ®Google Scholar
• Baquero F. Trends in antibiotic resistance of respiratory pathogens: an analysis and commentary on a collaborative surveillance study. J. Antimicrob. Chemother. 38(Suppl. A), 117–132 (1996).
   PubMedGoogle Scholar
• Canet J, Garau J. Importance of dose and duration of11-lactam therapy in nasopharyngeal colonization with resistant pneumococci. J. Antimicrob. Chemother. 50(Suppl. S2), 39–43 (2002).
   Google Scholar
• Blazquez J, Morosini MI, Negri MC, Gonzalez-Leiza M, Baquero F. Single amino acid replacements at positions altered in naturally occurring extended-spectrum TEM 11-lactamases. Antimicrob. Agents. Chemother. 39(1), 145–149 (1995).
   PubMedGoogle Scholar
• Negri MC, Lipsitch M, Blazquez J, Levin BR, Baquero F. Concentration-dependent selection of small phenotypic differences in TEM 11-lactamase-mediated antibiotic resistance. Antimicrob. Agents. Chemother. 44(9), 2485–2491 (2000).
   PubMedGoogle Scholar
• Low AS, MacKenzie FM, Gould IM, Booth IR. Protected environments allow parallel evolution of a bacterial pathogen in a patient subjected to long-term antibiotic therapy. Mal Microbial 42(3), 619–630 (2001).
   PubMedGoogle Scholar
• Blazquez J, Morosini MI, Negri MC, Baquero F. Selection of naturally occurring extended spectrum TEM 0-lactamase variants by fluctuating11-lactam pressure. Antimicrob. Agents. Chemother. 44(8), 2182-2184(2000).
   Google Scholar
• Galan JC, Morosini MI, Baquero MR, Reig M, Baquero E Haemophilus influenzae Lila ROB-1 mutations in hypermutagenic ampC Escherichia coli conferring resistance to cefotaxime andif-lactamase inhibitors and increases susceptibility to cefaclor. Antimicrob. Agents. Chemother 47(8), 2551–2557 (2003).
   PubMedGoogle Scholar
• Blazquez J, Negri MC, Morosini MI, Gomez-Gomez JM, Baquero E A237T as a modulating mutation in naturally occurring extended-spectrum TEM-Type 11-lactamases. Antimicrob. Agents. Chemother. 42(5), 1042–1044 (1998).
   PubMedGoogle Scholar
• Stratton CW. Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance. Emerg. Infect. Dis. 9(1), 10–16 (2003).
   PubMedGoogle Scholar
• Wise R Nasopharyngeal carriage of Stirptococcus pneumoniae a review of the potential role of pharmacokinetics and pharmacodynamics. J Antimicrob. Chemother. 50(Suppl. S2), 45–50 (2002).
   Google Scholar
• Garcia-Rey C, Aguilar L, Baquero F, Casal J, Dal-Re R Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae. J. Clin. Microbial 40(1), 159–164 (2002).
   PubMed Web of Science ®Google Scholar
• Pihlajamaki M, Kotilainen P, Kaurila T, Klaukka T, Palva E, Huovinen B Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents. Clin. Infect. Dis. 33, 483–488 (2001).
   PubMed Web of Science ®Google Scholar
• Doem GV. antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States. Clin. Infect. Dis. 33\(Suppl. 3), S187—S192 (2001).
   Google Scholar
• Gould IM, MacKenzie FM. Antibiotic exposure as a risk factor for emergence of resistance: the influence of concentration. J. Applied Microbial Symp. Supp. 92,78S-84S (2002).
   Google Scholar
• Davies TA, Dewasse BE, Jacobs MR, Applebaum PC. In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin and pristinamycin in Stirptococcus pneumoniae. Antimicrob. Agents. Chemother 44(2), 414 417 (2000).
   Google Scholar
• Leclercq R. Will resistance to ketolides develop in Streptococcus pneumoniae? J. Infect. 44(Suppl. A), 11–16 (2002).
   Google Scholar
• Edlund C, Alvan G, Barkholt L, Vacheron F, Nord CE. Pharmocokinetics and comparitive effects of telithromycin (HMR 3647) and darithromycin on the oropharyngeal and intestinal microflora. J. Antimicrob. Chemother. 46,741–749 (2000).
   PubMed Web of Science ®Google Scholar
• Rosato A, Vicarini H, Bonnefoy A, Chantot J, Ledercq R. A new ketolide, HMR 3004, active against streptococci inducibly resistant to erythromycin. Antimicrob. Agents. Chemother 42(6), 1392–1396 (1998).
   Google Scholar
• Geisel R, Scmitz FJ, Fluit AC, Labischinski H. Emergence, mechanism and clinical implications of reduced glycopeptide susceptibility in Staphylococcus aureus. Eur. J. Clin. Microbial Infect. Dis. 20,685–697 (2001).
   PubMed Web of Science ®Google Scholar
• Bernard L, Vaudaux P, Vuagnat A, et al. Effect of vancomycin therapy for osteomyelitis on colonisation by methicillin-resistant Staphylococcus aureus: lack of emergence of glycopeptide resistance. Infect. Control Hosp. Epidemial 24(9), 650–654 (2003).
   Google Scholar
• Casal J, Gimenez MJ, Aguilar L, et al. II-lactam activity against resistant pneumococcal strains is enhanced by the immune system. J. Antimicrob. Chemother. 50(Suppl. S2), 83–86 (2002).
   PubMedGoogle Scholar
• Casal J, Aguilar L, Jado I, et al. Effects of specific antibodies against Streptococcus pneumoniae on pharmacodynamic parameters ofif-lactams in a mouse sepsis model. Antimicrob. Agents. Chemother. 46(5), 1340–1344 (2002).
   PubMedGoogle Scholar